Retrieve all available abstracts of the following 230 articles: HTML format
Single Articles
KIM JM, Park S Risk stratification of pT1b urothelial carcinoma based on spatial relationships
between invasive tumour and muscularis propria on TURB specimens for predicting
muscle-invasive urothelial carcinoma in radical cystectomy: A new proposal.
Malays J Pathol. 2025;47:247-252. PubMed Abstract available
QUYNH NT, Nagata Y, Matsukawa T, Kashiwagi E, et al Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential
Chemopreventive Agent.
Cancer Genomics Proteomics. 2025;22:750-759. PubMed Abstract available
NAHKURI S, Weidle UH Bladder Cancer: Role of Circular RNAs in Oncogenesis, Tumor Suppression, and
Therapeutic Target Identification.
Cancer Genomics Proteomics. 2025;22:654-682. PubMed Abstract available
LIU J, Liu YX, Song YS, Liu CK, et al Targeting GRB2-Akt-SREBP1 signaling axis by saponins from Paris polyphylla Smith
var. yunnanensis (Franch.) Hand.-Mazz to overcome cisplatin resistance in bladder
cancer.
J Ethnopharmacol. 2025 Aug 27:120502. doi: 10.1016/j.jep.2025.120502. PubMed Abstract available
CHEN B, Zhang T, Wang Y, Li Z, et al Elevated C-reactive protein and D-dimer to predict venous thromboembolism in
patients with bladder cancer.
Front Immunol. 2025;16:1652139. PubMed Abstract available
HAN YE, Sung DJ, Cho HY, Yang KS, et al Multiparametric MRI Features of Plasmacytoid Urothelial Carcinoma of the Urinary
Bladder.
Korean J Radiol. 2025;26:832-840. PubMed Abstract available
LI Y, Liu S, Zhou M, Zhao Z, et al A COX-2-Targeted Platinum(lV) Prodrug Induces Apoptosis and Reduces Inflammation
in Bladder Cancer Models.
Pharmaceuticals (Basel). 2025;18:1185. PubMed Abstract available
GHERASIM RD, Chibelean C, Porav-Hodade D, Todea-Moga C, et al Microbiome Shifts in Bladder Cancer: A Narrative Review of Urobiome Composition,
Progression, and Therapeutic Impact.
Medicina (Kaunas). 2025;61:1401. PubMed Abstract available
DULF DV, Burnar AL, Dulf PL, Matei DR, et al Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality
of Bladder Cancer Patients Undergoing Radical Cystectomy.
J Clin Med. 2025;14:5810. PubMed Abstract available
GARCIA-RAYO C, Juste-Alvarez S, Gomez-Canizo C, Hernandez-Arroyo M, et al The Dynamic Field of Perioperative Treatment for Localized Muscle-Invasive
Bladder Cancer: A Review of the Current Research Landscape.
J Clin Med. 2025;14:5653. PubMed Abstract available
VERA G, Cerda-Infante J, Fernandez MI, Sanchez-Encinas M, et al Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A
Critical Review.
Bioengineering (Basel). 2025;12:866. PubMed Abstract available
ARTILES MEDINA A, Bajawi Carretero M, Lopez Perez E, Garach Fernandez S, et al Impact of Preoperative CT-Diagnosed Sarcopenic Obesity on Outcomes After Radical
Cystectomy for Bladder Cancer.
Cancers (Basel). 2025;17:2669. PubMed Abstract available
SHABBIR R, Quiles CG, Lane B, Zeef L, et al Gene Expression in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer Cells
Exposed to Hypoxia.
Cancers (Basel). 2025;17:2624. PubMed Abstract available
JANG SH, Kim MS Canonical correlations among symptom clusters, symptom experience, and symptom
cluster management in male patients with non-muscle invasive bladder cancer: a
cross-sectional study.
Eur J Oncol Nurs. 2025;78:102941. PubMed Abstract available
IKUMA S, Akatsuka J, Kaneko G, Takeda H, et al Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder
Cancer: A Retrospective Single-Center Study.
Curr Oncol. 2025;32:415. PubMed Abstract available
KAMATANI T, Umeda K, Iwasawa T, Miya F, et al Clonal diversity shapes the tumour microenvironment leading to distinct
immunotherapy responses in metastatic urothelial carcinoma.
Nat Commun. 2025;16:7995. PubMed Abstract available
MAHMOUDNEJAD N, Hamidi Madani M, Montazeri P, Vakili K, et al Clinical Predictive Factors for Reproductive Organ Involvement in Females with
Muscle Invasive Bladder Cancer: A Retrospective Review of Radical Cystectomy
Cases from Two Tertiary Centers.
Iran J Med Sci. 2025;50:530-538. PubMed Abstract available
TSENG WH, Lee CH, Lin RJ, Ho CH, et al Risk of Bladder Cancer in Patients with Chronic Indwelling Catheters: A
Real-World Data Analysis.
J Cancer. 2025;16:3464-3472. PubMed Abstract available
AKINTELURE D, Akintelure S, Al-Ibraheem HA Emerging Role of Multiparametric MRI in the Staging of Bladder Cancer: Insights
From the BladderPath Trial.
Cureus. 2025;17:e88623. PubMed Abstract available
JOHANSSON HB, Liedberg F, Bernardo C, Zadoroznyj A, et al Evaluation of gene expression-based predictors of lymph node metastasis in
bladder cancer.
Bladder Cancer. 2025;11:23523735251370895. PubMed Abstract available
CORDARO F, Barresi A, Bencivinni F, Banco A, et al Carcinomatous leptomeningitis from bladder cancer mimicking immune-related
cerebellitis: A case report.
Neurol Sci. 2025 Aug 27. doi: 10.1007/s10072-025-08425. PubMed Abstract available
WANG D, Ai L, Tan H, Yan Y, et al A urinary DNA methylation assay using two genes enables noninvasive detection and
prognostic prediction in urothelial carcinoma.
Sci Rep. 2025;15:31281. PubMed Abstract available
HAN G, Wang X, Li Z, Yang K, et al Robot-Assisted Boari-flap after Orthotopic Neobladder Using the KangDuo Surgical
Robot-01 System.
Int Braz J Urol. 2026;52:e20250341. PubMed Abstract available
VOLZ Y, Eismann L, Westhofen T, Pyrgidis N, et al Physical activity matters: prognostic impact of preoperative functioning scores
in patients undergoing radical cystectomy.
World J Urol. 2025;43:512. PubMed Abstract available
LIU Z, Cong X, Chen C, Yin J, et al Development and landscape of maintenance therapy after first-line treatment of
advanced or metastatic urothelial carcinoma.
Front Immunol. 2025;16:1541213. PubMed Abstract available
ATSUTA M, Urabe F, Iwatani K, Kubo M, et al Clinical utility of a novel perioperative quality assessment metric, trifecta,
for radical cystectomy.
Int J Clin Oncol. 2025;30:1832-1840. PubMed Abstract available
JURADO LF, Daman AW, Li Z, Ross VMS, et al A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus
Calmette-Guerin via reprogramming granulopoiesis.
Immunity. 2025;58:1984-2001. PubMed Abstract available
RIZKALLA CN, Tretiakova M, Suarez CJ, Williamson SR, et al Urothelial carcinoma with osteoclast-like giant cells: An expanded
immunohistochemical and molecular profile.
Am J Clin Pathol. 2025;164:257-264. PubMed Abstract available
SU X, Mo X, Kan J, Yang F, et al Decoding the genetic links between substance use disorder and cancer
vulnerability.
Psychopharmacology (Berl). 2025;242:2021-2033. PubMed Abstract available
CHANG KH, Chen HC, Chen CY, Tsai SP, et al Natural lignan justicidin A-induced mitophagy as a targetable niche in bladder
cancer.
Chem Biol Interact. 2025 Sep 3:111723. doi: 10.1016/j.cbi.2025.111723. PubMed Abstract available
MISRA S, Bisht R, Motiwala ZY, Puniyani A, et al Is it prime time for stent-less robotic radical cystectomy? A scoping review.
J Robot Surg. 2025;19:560. PubMed Abstract available
WANG B, Wu K, Cui Y, Han X, et al Effects of a Dendritic Cell Vaccine Loaded With Whole Tumor Antigen on Bladder
Cancer Model in hu-PBL-SCID Mice.
Drug Dev Res. 2025;86:e70157. PubMed Abstract available
CHAUMEL M, Brichart N, Bruyere F, Bourgi A, et al Impact of COVID-19 care reorganization on the prognosis of patients with bladder
urothelial carcinoma: a multicentric retrospective study.
Can J Urol. 2025;32:359-366. PubMed Abstract available
TAN Z, Huang Y, Fu S, Li H, et al Construction of a gene-metabolite-microbiome regulatory network reveals novel
therapeutic targets in bladder cancer through multi-omics analysis.
Ann Med. 2025;57:2553220. PubMed Abstract available
DEYHIMFAR R, Gholami K, Oskouie IM, Baghdadabad LZ, et al High-dose vitamin C improves BCG immunotherapy's efficacy in a murine ectopic
model of bladder cancer.
Pathol Res Pract. 2025;275:156207. PubMed Abstract available
GENG R, Shang H, Chen Z, Tang K, et al ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and
enhanced immune checkpoint inhibitor therapy in bladder cancer.
Biomaterials. 2025;326:123677. PubMed Abstract available
CARAPITO A, Fernandes Ferreira VS, Silva Ferreira AC, Teixeira-Marques A, et al Non-invasive bladder cancer detection: Identification of a urinary volatile
biomarker panel using GC-MS metabolomics and machine learning.
Talanta. 2025;297. PubMed Abstract available
CHIUJDEA S, Petrut B, Martha O, Chiujdea AL, et al Prognostic Factors of Long-Term Survival in Non-Muscle-Invasive Bladder Cancer:
An 18-Year Retrospective Study from Real-Life Practice.
Chirurgia (Bucur). 2025;120:459-466. PubMed Abstract available
RADU CG, Radavoi GD, Aurelian J, Achim IF, et al Bricker Urinary Diversion after Radical Cystectomy: A Comparative Analysis of
Laparoscopic vs. Robotic Approach in Terms of Quality of Life, Perioperative
Outcomes and Postoperative Complications.
Chirurgia (Bucur). 2025;120:446-458. PubMed Abstract available
JEONG IS, Seo JW, Park SJ, Kim SY, et al Deep learning-driven whole-slide image analysis predicts chemo-resistance and
motility subtypes in muscle-invasive bladder cancer.
Genes Genomics. 2025 Sep 4. doi: 10.1007/s13258-025-01677. PubMed Abstract available
BIGLIA A, Sacchi MC, Maggiore F, Morandi V, et al Case report: atypical anti-SAE1 autoantibody manifestation with splinter
hemorrhages as onset, and related to urothelial cancer.
Eur Rev Med Pharmacol Sci. 2025;29:398-403. PubMed Abstract available
MENG L, Zhu X, Ji X, Wang B, et al Advances in the immunological microenvironment and immunotherapy of bladder
cancer.
Front Immunol. 2025;16:1609871. PubMed Abstract available
BAKALOUDI DR, Koehne EL, Voutsinas JM, Diamantopoulos LNu, et al Agreement between transurethral resection of bladder tumor and radical cystectomy
pathology in patients with bladder cancer subtype histology: A retrospective
cohort study.
Urol Oncol. 2025 Sep 2:S1078-1439(25)00282-0. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
MAURYA N, Singh R, Goel A, Singhai A, et al Correction to "Clinicohistopathological implications of phosphoserine 9 glycogen
synthase kinase-3beta/ beta-catenin in urinary bladder cancer patients".
World J Clin Oncol. 2025;16:107778. PubMed Abstract available
SO SW, Han JH, Yuk HD, Jeong CW, et al High carbohydrate antigen 19-9 levels indicate poor prognosis in patients with
bladder cancer following radical cystectomy.
Front Oncol. 2025;15:1550203. PubMed Abstract available
RINGIA JB, Scholte FEF, Lijnen RAG, Algie E, et al Routine annual imaging does not aid in diagnosing new functional complications
more than five years after RC with ileal conduit.
World J Urol. 2025;43:539. PubMed Abstract available
MALMSTROM PU, Wang EYH Paradigm shift in the treatment of bladder cancer? The Swedish perspective.
Scand J Urol. 2025;60:186-188. PubMed Abstract available
LIEDBERG F, Baseckas G, Blackberg M, Fridriksdottir R, et al Survival patterns after perioperative treatment escalation and cystectomy for
synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.
Scand J Urol. 2025;60:173-179. PubMed Abstract available
CHUANG AE, Tao YK, Fan YJ, Chiu HJ, et al Synergistic nanoplatform of M1 macrophage-derived extracellular vesicles and
MoS(2) for tumor-targeted photoimmunotherapy in bladder cancer.
Nanoscale. 2025 Sep 3. doi: 10.1039/d5nr00374. PubMed Abstract available
LI T, Zhu K, Tong H, Sun Y, et al Cancer-associated fibroblast derived CXCL14 drives cisplatin chemoresistance by
enhancing nucleotide excision repair in bladder cancer.
J Exp Clin Cancer Res. 2025;44:265. PubMed Abstract available
PARK JH, Lee S, Jeong SH, Ku JH, et al The effect of neoadjuvant chemotherapy on survival outcomes subsequent to radical
cystectomy in pathological T0 bladder cancer patients: A multicenter large-scale
analysis.
Investig Clin Urol. 2025;66:395-404. PubMed Abstract available
OH JJ, Hong SK Contemporary management of metastatic urothelial carcinoma.
Investig Clin Urol. 2025;66:375-382. PubMed Abstract available
SAHARTI SN, Almutairi FM Trends in genitourinary tumors: Academic center experience over 16 years.
Saudi Med J. 2025;46:985-991. PubMed Abstract available
MOSE L, Maitre P, Eberz P, Zilli T, et al Treatment approaches for non-metastatic small cell bladder cancer: a
meta-analysis of reconstructed Kaplan-Meier curves.
Clin Transl Radiat Oncol. 2025;55:101032. PubMed Abstract available
SHI M, Meng X, Xu X, Wang Q, et al Gene and pathway analysis of genome-wide genetic associations of bladder cancer.
Curr Urol. 2025;19:321-330. PubMed Abstract available
GONZALEZ V, Linton E, Boyce T, Dahmoush L, et al Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in
treatment of small cell bladder cancer.
Urol Case Rep. 2025;62:103165. PubMed Abstract available
WANG T, Ding F, Sun K Construction and immunohistochemical validation of a necroptosis-related
prognostic signature in bladder cancer and its association with tumor immune
infiltration.
Front Genet. 2025;16:1527907. PubMed Abstract available
XU D, Li Q Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of
Neuroendocrine Bladder Cancer.
Cancer Heterog Plast. 2025;2:10. PubMed Abstract available
DING Y, Pan Y, Geyer CR, Vizeacoumar FJ, et al Unraveling bladder cancer-related circRNA biomarkers: a hybrid model combining
deep learning and statistics.
Health Inf Sci Syst. 2025;13:53. PubMed Abstract available
ALIMOHAMED NS, Gotto G, Kulkarni GS, Black PC, et al A population-based analysis of patterns of care in patients with de novo
muscle-invasive bladder cancer from Alberta, Canada.
Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9111. PubMed Abstract available
KANAAN MF, Breau RH, Lavallee LT, McIsaac DI, et al Testosterone replacement therapy and bladder cancer.
Can Urol Assoc J. 2025 Aug 28. doi: 10.5489/cuaj.9207. PubMed Abstract available
POOCHI SP, Sundarraj R, Raju MV, Kaniyur Chandrasekaran M, et al Harnessing Nature: Computational and Experimental Insights Into Ipomoea obscura
Metabolites for Bladder Cancer Therapy.
Chem Biodivers. 2025 Sep 2:e00909. doi: 10.1002/cbdv.202500909. PubMed Abstract available
AN W, Shen D, Li D, Shen J, et al Unmasking disparities in bladder cancer outcomes in the disaggregated Asian
American population.
Expert Rev Anticancer Ther. 2025 Sep 3:1-10. doi: 10.1080/14737140.2025.2556884. PubMed Abstract available
SHI Z, Luo Z, Luo W, Zhao B, et al Letter to the editor: "bladder cancer isn't BPH: why TURBT patients deserve
separate risk models for complicated UTI".
World J Urol. 2025;43:527. PubMed
SORIA F, Mari A, Moschini M, Naspro R, et al The current role of photodynamic diagnosis (PDD) in the management of non-muscle
invasive bladder cancer: the Italian Society of Urology (SIU) Position Paper.
Minerva Urol Nephrol. 2025;77:443-450. PubMed Abstract available
ERNST VS, Manz K, Weitmann K, Hoffmann W, et al Assessing cancer risk in firefighters in Northern Germany: a retrospective cohort
study.
BMC Public Health. 2025;25:2998. PubMed Abstract available
CHEN K, Chen J, Cong Y, He Q, et al Correction: TTK promotes mitophagy by regulating ULK1 phosphorylation and
pre-mRNA splicing to inhibit mitochondrial apoptosis in bladder cancer.
Cell Death Differ. 2025 Sep 1. doi: 10.1038/s41418-025-01571. PubMed
ZHAO L, Xu Z, Ren L, Zheng S, et al Investigating the relationship between peripheral blood transferrin receptor
protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.
Sci Rep. 2025;15:32197. PubMed Abstract available
DU C, Wei W, Hu M, He J, et al Multi-DECT Image-based Interpretable Model Incorporating Habitat Radiomics and
Vision Transformer Deep Learning for Preoperative Prediction of Muscle Invasion
in Bladder Cancer.
Acad Radiol. 2025 Aug 30:S1076-6332(25)00756-1. doi: 10.1016/j.acra.2025. PubMed Abstract available
HU L, Hu JW, Wang CQ, Li RY, et al Neoadjuvant PD-1/PD-L1 Inhibitors for Muscle-Invasive Bladder Cancer: A
Meta-Analysis.
Clin Genitourin Cancer. 2025;23:102408. PubMed Abstract available
LINDLAND K, Juzeniene A Cytotoxicity of (212)Pb-labeled anti-PTK7 antibody in 2D adherent and 3D
multicellular bladder cancer models.
EJNMMI Radiopharm Chem. 2025;10:58. PubMed Abstract available
NECCHI A, Guerrero-Ramos F, Crispen PL, Herrera-Imbroda B, et al TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in
patients with muscle-invasive bladder cancer who are ineligible for or decline
neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a
randomised, open
Lancet Oncol. 2025 Aug 27:S1470-2045(25)00358. PubMed Abstract available
MI W, Zang C, Zhao J, Kamat AM, et al Mixed-grade papillary urothelial carcinoma with a minor high-grade component
shows a significantly worse clinical outcome than low-grade papillary urothelial
carcinoma.
Hum Pathol. 2025;163:105904. PubMed Abstract available
CHAN E, Stohr BA, Sangoi AR, Sirohi D, et al Invasive urothelial carcinoma with chordoid and myxoid features shows increased
RAS/RAF pathway alterations.
Hum Pathol. 2025;163:105882. PubMed Abstract available
POWLES TB, Grande E, Alimohamed N, Oliveira N, et al SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally
advanced or metastatic urothelial carcinoma.
Future Oncol. 2025;21:2705-2712. PubMed Abstract available
WANG XL, Cao L, Wang YW, Chu T, et al Role of 3-mercaptopyruvate sulfurtransferase in cancer.
Cell Signal. 2025;135:112020. PubMed Abstract available
AMINSHARIFI A, Saran Manivasagam S, Askarpour MR, Raman JD, et al Is organ preserving radical cystectomy in women oncologically safe and does it
improve quality of life?
Expert Rev Anticancer Ther. 2025;25:1075-1085. PubMed Abstract available
INDULKAR S, Rao BV, Das D, Pasam MK, et al Deciphering the Molecular Landscape of Urothelial Carcinoma:
Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for
Cost-effective Stratification.
Appl Immunohistochem Mol Morphol. 2025;33:267-276. PubMed Abstract available
DELAHUNT B, Johannsen S, Egevad L, Yaxley JW, et al High proportion of clinically significant prostate adenocarcinomas in radical
cystoprostatectomy specimens following complete prostate sampling.
Pathology. 2025;57:708-711. PubMed Abstract available
SABER TANHA A, Raeisi N, Jafari Zarrin Ghabaei F, Aryana K, et al Comparable Diagnostic Performance of 99m Tc-FAPI Scintigraphy and
Contrast-enhanced CT in Restaging a Rare Case of Metastatic Colon Adenocarcinoma
to the Urachus.
Clin Nucl Med. 2025;50:e626-e627. PubMed Abstract available
UNTERRAINER LM, Schmid HP, Kunte SC, Holzgreve A, et al (68)Ga-FAPI and (18)F-FAPI PET/CT for detection of nodal metastases prior radical
cystectomy in high-risk urothelial carcinoma patients.
Eur J Nucl Med Mol Imaging. 2025;52:3963-3974. PubMed Abstract available
PERLIN D V, Shmanev A O, Shamkhalov Sh N, Zipunnikov V P, et al [Recurrence of urothelial bladder cancer in the upper urinary tract after radical
cystectomy: is there prevention and what are the treatment options?].
Urologiia. 2025;:59-63. PubMed Abstract available
DMITRIEVA T A, Popov A Y, Gritskevich A A, Makarov V A, et al [Review of current methods of diagnosis and treatment of locally advanced
urothelial bladder cancer].
Urologiia. 2025;:96-102. PubMed Abstract available
AKINTELURE D, Tawose P, Akintelure S, Agada R, et al Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and
Challenges.
Cureus. 2025;17:e89801. PubMed Abstract available
CHE K, Qian D, Cui S, Xie F, et al Dissecting Causal Relationships Between Gut Microbiota, Plasma Metabolites and
Bladder Cancer: A Two-Step Mendelian Randomization Study.
Health Sci Rep. 2025;8:e71206. PubMed Abstract available
HUANG J, Zhou C, Yu Z, Song Z, et al A novel prognostic biomarker DUSP6 promote the malignant progression of bladder
cancer through mTOR mediated mitophagy.
Front Oncol. 2025;15:1603069. PubMed Abstract available
ZHOU Q, Ma L, Yu Y, Zhang C, et al Development of a radiomics and clinical feature-based nomogram for preoperative
prediction of pathological grade in bladder cancer.
Front Oncol. 2025;15:1661979. PubMed Abstract available
PETRELLI F, Dottorini L, Ghidini A, Ceresoli F, et al Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder
cancer: A network meta-analysis.
Urol Oncol. 2025 Sep 10:S1078-1439(25)00333. PubMed Abstract available
LIU Y, Liu L, Yao Z, Hou Y, et al Applications and future prospects of laser technologies in the treatment of
non-muscle invasive bladder cancer.
Bladder (San Franc). 2025;12:e21200050. PubMed Abstract available
ZHONG H, He W, Mo M, Tong S, et al Neoadjuvant therapy plus thulium laser transurethral bladder tumor resection for
muscle-invasive bladder cancer.
Bladder (San Franc). 2025;12:e21200053. PubMed Abstract available
BENZEKRY I, Klein I, Pavlov A, Dekel Y, et al [MASSIVE TUMOR INSIDE A GIANT BLADDER DIVERTICULUM].
Harefuah. 2025;164:529-531. PubMed Abstract available
FAZAA N, Shashar R, Malshy K, Amiel G, et al [INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE
INVASIVE PATIENTS].
Harefuah. 2025;164:524-528. PubMed Abstract available
WEN L, Miyagi H, Spiess PE, Yu A, et al Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment
strategies and emerging therapies.
Nat Rev Urol. 2025 Sep 10. doi: 10.1038/s41585-025-01072. PubMed Abstract available
CHANG K, Delavan HM, Yip E, Kasap C, et al Modulating the PPARgamma pathway upregulates NECTIN4 and enhances chimeric antigen
receptor (CAR) T cell therapy in bladder cancer.
Nat Commun. 2025;16:8215. PubMed Abstract available
HOSSAIN MN, Das D, Mostofa MA, Hosen MI, et al Targeted hotspot profiling reveals a functionally relevant mutation in bladder
cancer.
Urol Oncol. 2025 Sep 9:S1078-1439(25)00317-5. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
YANG X, Wang L, Lin P, Ning Y, et al Corrigendum to "Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders
for the treatment of bladder cancer" [Eur. J. Med. Chem. 293 (2025) 117710].
Eur J Med Chem. 2025 Sep 10:118140. doi: 10.1016/j.ejmech.2025.118140. PubMed
SAKATANI T, Tanaka S, Murakami K, Aguilar F, et al Development and analytical validation of a multiplex diagnostic qPCR-array as a
potential application in predicting the response to neoadjuvant chemotherapy in
muscle invasive bladder cancer.
Transl Oncol. 2025;61:102528. PubMed Abstract available
XIE H, Yi X, Wei W A commentary on "A nomogram for predicting lymph node metastases in nonmetastatic
muscle-invasive bladder cancer: a SEER-based investigation".
Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003346. PubMed
MASTROIANNI R, Iannuzzi A, Ragusa A, Tuderti G, et al Impact of pad wetness on health-related quality of life after radical cystectomy
and orthotopic neobladder.
World J Urol. 2025;43:548. PubMed Abstract available
LIU L, Liu Z, Fan L, Yao Z, et al An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG
to assess prognosis and immunotherapy response in bladder cancer patients.
Elife. 2025;13:RP95326. PubMed Abstract available
ZHANG D, Ren J, Ye J, Wu R, et al Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003371. PubMed Abstract available
CHAVES MEDINA MJ, Villada Florez D, Castaneda Millan DA, Garcia-Perdomo HA, et al Using epigenetics as an alternative treatment for bladder cancer: A literature
review.
Urologia. 2025 Sep 10:3915603251372377. doi: 10.1177/03915603251372377. PubMed Abstract available
DONG J, Guo Y, Ji T, Guan H, et al Puerariae radix flavones induce apoptosis in bladder cancer T24 cells via the
FAS/TNFR1 pathway: A potential therapeutic candidate.
Biomed Rep. 2025;23:170. PubMed Abstract available
LI J, Song Y, Chen R, Gao H, et al Evaluating repeat transurethral resection after en bloc resection for non-muscle
invasive bladder cancer.
Ther Adv Urol. 2025;17:17562872251367555. PubMed Abstract available
CAO T, Li N, Guo C, Zhang H, et al CT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the
Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two
Years after TURBT.
Curr Med Imaging. 2025 May 26. doi: 10.2174/0115734056350444250418075406. PubMed Abstract available
BROOKS G, Ghidini F, Virgone C, De Corti F, et al Long-term complications in patients with bladder-prostate rhabdomyosarcoma
treated with brachytherapy: a systematic review.
Pediatr Surg Int. 2025;41:290. PubMed Abstract available
XIE JL, Li XJ, Zhang YL, Zheng YY, et al [Primary lymphomas in urinary bladder: a clinicopathological analysis of 23
cases].
Zhonghua Bing Li Xue Za Zhi. 2025;54:925-931. PubMed Abstract available
LU K, Chao L, Wang J, Wang X, et al Erratum: Risk Score Model of Aging-Related Genes for Bladder Cancer and Its
Application in Clinical Prognosis.
JCO Clin Cancer Inform. 2025;9:e2500251. PubMed
ZHOU L, Yu G, Zheng Z, Xu B, et al IGHA1 and IGHG1 Expression Panel Predicts Anti-PD-L1 Response in Muscle-Invasive
Bladder Cancer.
Mol Carcinog. 2025 Sep 8. doi: 10.1002/mc.70033. PubMed Abstract available
DA Y, Lu Z, Zhu Z, Tai H, et al A high stroma-tumor ratio is associated with an immunosuppressive tumor
microenvironment and a poor prognosis in bladder cancer.
Front Oncol. 2025;15:1604609. PubMed Abstract available
LIU Y, Lv H, Chen Y, Ye S, et al Cu(2)(OH)PO(4)@PAA Nanoparticles for Highly Effective Combination of
Chemodynamic, Photodynamic and Photothermal Therapies Against Bladder Cancer.
Int J Nanomedicine. 2025;20:10701-10719. PubMed Abstract available
LIU X, Ding G, Liu Y, Yan X, et al Epigenetic regulation of bladder cancer in the context of aging.
Front Pharmacol. 2025;16:1617452. PubMed Abstract available
PENG L, Cai T, Xu P, Chen C, et al Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of
PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response.
Oncol Res. 2025;33:2463-2489. PubMed Abstract available
HUANG W, Chao F, Hsu JC, Sun X, et al Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer
and bladder cancer using [(89)Zr]Zr-DFO-Durvalumab.
Colloids Surf A Physicochem Eng Asp. 2025;723:137332. PubMed Abstract available
NAM KC, Park BJ Antibacterial and anticancer activity of multifunctional iron-based magnetic
nanoparticles against urinary tract infection and cystitis-related bacterial
strains and bladder cancer cells.
Biomed Eng Lett. 2025;15:903-915. PubMed Abstract available
WANG L, Ren D, Cai Z, Hu W, et al O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor
suppressor gene PER1 via m(6)A modification.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:827-839. PubMed Abstract available
MICHALIK T, Wrobel M, Fedorowicz S, Michalik K, et al [Bladder cancer in geriatric patients].
Med Pr. 2025 Sep 1:209113. doi: 10.13075/mp.5893.01621. PubMed Abstract available
FANG Q, You C, Xiao X, Liu Y, et al Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer:
Mechanisms and Therapeutic Targeting.
Protein Pept Lett. 2025 Sep 3. doi: 10.2174/0109298665403178250806111943. PubMed Abstract available
NASSAR O, Farahat IG Prostate sparing radical cystectomy and neobladder: institutional long-standing
qualified consideration.
J Egypt Natl Canc Inst. 2025;37:58. PubMed Abstract available
BAI K, Pingle SR, Chung R, Joffe BI, et al Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive
non-muscle-invasive bladder cancer.
Urol Oncol. 2025 Sep 6:S1078-1439(25)00313-8. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
CONG B, Liu H, Sun M, Hu D, et al Bisphenol A exposure promotes proliferation and invasion capabilities of bladder
cancer cells: Insights from gene expression and pathway analysis.
Toxicol Lett. 2025 Sep 5:S0378-4274(25)01577. PubMed Abstract available
WANG K, Gu Q, Xue C, Shi J, et al MAP30 inhibits proliferation and metastasis of bladder cancer by increasing EGR1
expression and promoting the transcriptional activation of DUSP1.
Mol Immunol. 2025;187:48-60. PubMed Abstract available
XU X, Liang Z, Feng Y, Qi H, et al Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal
Neobladder with Integrated Pelvic Fascial Structure-Sparing in Males with Bladder
Cancer.
Urol J. 2025 Sep 6. doi: 10.22037/uj.v22i.8450. PubMed Abstract available
WANG Z, Shi H, Wang Q, Huang Y, et al AI-driven and Traditional Radiomic Model for Predicting Muscle Invasion in
Bladder Cancer via Multi-parametric Imaging: A Systematic Review and
Meta-analysis.
Acad Radiol. 2025 Sep 5:S1076-6332(25)00806-2. doi: 10.1016/j.acra.2025. PubMed Abstract available
RODRIGUEZ PENARANDA N, Di Bello F, Marmiroli A, Falkenbach F, et al Cancer-specific mortality in secondary bladder cancer after nephroureterectomy
for upper tract urothelial carcinoma.
Urol Oncol. 2025 Sep 5:S1078-1439(25)00312-6. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
DAI H, Zhang Y, Yu S, Feng Y, et al miR-19b-3p Affects the Proliferation and Apoptosis of Bladder Cancer Cells by
Regulating the Stability of lncRNA SNHG20.
Appl Biochem Biotechnol. 2025 Sep 6. doi: 10.1007/s12010-025-05370. PubMed Abstract available
ROBERSON DS, McLeay MT 2nd, Henning G, Morales-Martinez G, et al The impact of prophylactic incisional negative pressure wound therapy on surgical
site infection following open radical cystectomy.
Urol Oncol. 2025;43:586-593. PubMed Abstract available
JUNLAPAK N, Khumngern S, Nontipichet N, Kangkamano T, et al A label-free electrochemical immunosensor for bladder tumor marker NMP22 using
AuNPs@OMC and Thi@Gr-COOH nanocomposites.
Bioelectrochemistry. 2026;167:109074. PubMed Abstract available
CHOW RD, Mamtani R Assessment of synergistic vs. independent drug activity for enfortumab vedotin
and pembrolizumab in untreated advanced urothelial carcinoma.
Urol Oncol. 2025;43:597. PubMed Abstract available
HAIDER CG, Wang Q, Wang G, Wang Y, et al Copy number variations in urine cell-free DNA from bladder neoplasm patients.
Mol Cell Probes. 2025;83:102044. PubMed Abstract available
MOON HH, Aragon-Ching JB, Thompson A, Abraham A, et al Early real-world utilization of avelumab switch maintenance among patients with
advanced urothelial carcinoma without progression following treatment with
first-line platinum-based chemotherapy.
Urol Oncol. 2025;43:594. PubMed Abstract available
HART LJ, Barker K, Ruzdija D, Bertolo A, et al Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on
social determinants of health.
Urol Oncol. 2025;43:596. PubMed Abstract available
GAZZONI G, Michelon I, Vilbert M, Oliveira JP, et al Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma:
A systematic review and meta-analysis.
Urol Oncol. 2025;43:595. PubMed Abstract available
BERTOLO R, Cianflone F, Pettenuzzo G, Costantino S, et al The impact of early versus delayed ureteral ligation on renal function after
robot-assisted radical cystectomy.
Eur J Surg Oncol. 2025;51:110213. PubMed Abstract available
HAYASHI A, Maeda S, Yamazaki A, Nakamura T, et al Urinary lipid production in dogs with urothelial carcinoma.
Vet J. 2025;313:106373. PubMed Abstract available
CHEN F, Simsir A, Cheng L Molecular testing in urinary cytology specimens: Current status and future
directions.
Urol Oncol. 2025;43:565-578. PubMed Abstract available
LOPES M, Pereira J, Temido MJ, Gama J, et al Prognostic value of combined tumor regression grade and TNM stage in
muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical
cystectomy.
Arch Ital Urol Androl. 2025 Sep 17:14264. doi: 10.4081/aiua.2025.14264. PubMed Abstract available
LAI Y, Peng Z, He Z, Lu Z, et al Dioscin initiates dual roles in bladder cancer progression via
miR-195-5p/FASN/SLC3A2 axis-mediated cell death mechanisms.
Transl Oncol. 2025;61:102534. PubMed Abstract available
SQUIRES P, Cook EE, Song Y, Wang CY, et al Real-world economic burden of disease recurrence in patients with muscle-invasive
bladder cancer: A population-level claims-based analysis.
J Manag Care Spec Pharm. 2025 Sep 17:1-11. doi: 10.18553/jmcp.2025.25106. PubMed Abstract available
WILLIAMS C, Talwar R, Ramchandani P, Smith AL, et al Characterizing pelvic organ descent in women after radical cystectomy: an
exploratory analysis.
World J Urol. 2025;43:559. PubMed Abstract available
WANG J, Yang J, Yao K, Tan J, et al m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating
FOXC1 to promote PARK7 transcriptional activity.
Chin Med J (Engl). 2025 Sep 16. doi: 10.1097/CM9.0000000000003744. PubMed Abstract available
MARKOVIC G, Resnik N, Janev A, Zupancic D, et al The role of focal adhesion kinase in bladder cancer: translation from in vitro to
ex vivo human urothelial carcinomas.
Radiol Oncol. 2025;59:349-367. PubMed Abstract available
CHEN H, Ma L, Ji Z, Dong J, et al FAM174B remodels the tumor microenvironment, inhibits the infiltration of
macrophage, predicts the molecular subtype and therapeutic response of bladder
cancer.
Int J Med Sci. 2025;22:3737-3748. PubMed Abstract available
HAN Y, Li C, Wu G Comment on "IGF2BP3 promotes the proliferation and cisplatin resistance of
bladder cancer by enhancing the mRNA stability of CDK6 in an m(6)A dependent
manner".
Int J Biol Sci. 2025;21:5284-5286. PubMed
LANG Y, Li P, He R, Zhu B, et al Dynamic changes of urinary microbiota in patients with bladder cancer after
surgery and its clinical significance.
Front Immunol. 2025;16:1638628. PubMed Abstract available
HIONG A, Lynam J, Weickhardt A, Wong S, et al Perioperative chemotherapy use and related outcomes in muscle-invasive bladder
cancer in Australia.
BJUI Compass. 2025;6:e70083. PubMed Abstract available
LIU Y, Li J, Liang G, Fang F, et al The mediating effect of dyadic coping between illness perception and fear of
disease progression in bladder cancer patients: A cross-sectional survey.
Medicine (Baltimore). 2025;104:e44520. PubMed Abstract available
LIU Z, Tu J, Long J, Guo L, et al Causal relationships between immune cells and common urinary system tumors: A
bidirectional analysis of Mendelian randomization.
Medicine (Baltimore). 2025;104:e44297. PubMed Abstract available
TIAN S, Wang C, Zhao X, Xuan Y, et al A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance
in bladder cancer.
Transl Oncol. 2025;61:102537. PubMed Abstract available
GUPTA S, Lee JK, Mitchell J, Huang RSP, et al Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune
Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma.
JCO Precis Oncol. 2025;9:e2500257. PubMed Abstract available
IBRAHEEM N, Abosheisha M, Alemam A, Abbas M, et al Integrated Magnetic Resonance Imaging in Muscle-Invasive Bladder Cancer: A
Comprehensive Review.
Cureus. 2025;17:e90077. PubMed Abstract available
HABAZ IA, Ou X, Wang NI, Schincaglia A, et al MAIT cells promote cancer progression and regulatory T cell accumulation in
bladder tumor microenvironment.
J Immunother Cancer. 2025;13:e012496. PubMed Abstract available
SIMOES GCS, Calderon J, Claros OR, Alfer W, et al Robotic Partial Cystectomy for Urachal Adenocarcinoma: Surgical Technique with
Cys-toscopic Correlation.
Int Braz J Urol. 2026;52:e20250446. PubMed Abstract available
SHEBANI MAA, Ikdees AA, Alazeebi SY, Nagib E, et al A Multifactorial Case of Retroperitoneal Fibrosis in a Post-radiation Bladder
Cancer Patient: Diagnostic and Therapeutic Challenges.
Cureus. 2025;17:e89976. PubMed Abstract available
SHAO Y, Guan Y, Zhao J, Abudurexiti M, et al Alternating intravesical instillation of Bacillus Calmette-Guerin and Pseudomonas
aeruginosa effectively prevents postoperative recurrence in high-risk
non-muscle-invasive bladder cancer.
Am J Transl Res. 2025;17:6619-6629. PubMed Abstract available
GOTO T, Akai T, Teramoto Y, Miyamoto H, et al Latrophilin-1 and latrophilin-2 as androgen receptor-responsive G protein-coupled
receptors promote bladder cancer progression.
Am J Transl Res. 2025;17:6403-6413. PubMed Abstract available
HASHIMOTO M, Fukiage K, Taniguchi K, Minami T, et al Upper urinary tract urothelial carcinoma patients show better overall response
rate than bladder cancer patients during enfortumab vedotin treatment following
pembrolizumab.
Transl Androl Urol. 2025;14:2279-2288. PubMed Abstract available
CAO J, Zheng W Angiogenesis-related gene NID2 profiling and immune infiltration in bladder
cancer: prognostic implications and immunotherapy response.
Front Immunol. 2025;16:1615173. PubMed Abstract available
HUANG X, Wang X, He Z, Huang Y, et al Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle
Invasive Bladder Cancer.
Cancer Med. 2025;14:e71243. PubMed Abstract available
DAVIDSSON S, Jerlstrom T, Carlsson J Optimizing Tissue Sampling Timing for Accurate Gene Expression Analysis.
Int J Mol Sci. 2025;26:8581. PubMed Abstract available
DEVAR J, Elebo N, Makan A, Pincus A, et al Distinct Metabolomic and Lipoprotein Signatures in Gall Bladder Cancer Patients
of Black African Ancestry.
Cancers (Basel). 2025;17:2925. PubMed Abstract available
SETTI BOUBAKER N, Gurtner A, Boussetta S, Manni I, et al Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From
Molecular Characterization to Clinical Applicability.
Cancers (Basel). 2025;17:2768. PubMed Abstract available
PARK IW, Noh TI, Kang SH, Oh JJ, et al Demonstrating the non-inferiority of robotic radical cystectomy for cT3-cT4
urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity
score-matched analysis.
J Robot Surg. 2025;19:596. PubMed Abstract available
ISHII N, Sekine Y, Shinohara M, Kawashima Y, et al Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World
Multicenter Study.
Cancer Med. 2025;14:e71241. PubMed Abstract available
URUSHIBARA M, Kato D, Okumura T, Kojima A, et al Long-Term Survival Obtained by Repeated Cytoreductive Surgery and S-1 Plus
Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With
Metastatic Urachal Carcinoma: A Case Report.
Cancer Rep (Hoboken). 2025;8:e70317. PubMed Abstract available
HAN T, Cui H, Du G, Guan Y, et al Expression and Prognostic Significance of Different Antibody-Drug Conjugate
Target Proteins in Urachal Carcinoma.
Clin Genitourin Cancer. 2025;23:102403. PubMed Abstract available
YANG T, Sun X, Chen J, Li J, et al MS4A4A-positive tumor-associated macrophages associate with poor prognosis and
T-cell exhaustion in patients with urothelial carcinoma of the bladder.
J Pathol. 2025;267:225-239. PubMed Abstract available
GALSKY MD, Bajorin DF, Tomita Y, Ye D, et al Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker
analysis of the randomized phase 3 CheckMate 274 trial.
Nat Med. 2025;31:3062-3073. PubMed Abstract available
HAN W, Yu X, Chen S, Ou Z, et al Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A
20-Year Nationwide Center Experience.
Clin Genitourin Cancer. 2025;23:102397. PubMed Abstract available
KHANI F, Beg S, Park K, Kawaguchi K, et al SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma
in situ and urothelial dysplasia.
Pathol Res Pract. 2025;273:156148. PubMed Abstract available
SLUSARCZYK A, Scilipoti P, Contieri R, Longoni M, et al Comparative Assessment of Chemotherapy Followed by Consolidative Radical
Cystectomy Versus Chemoradiation for Clinically Node-Positive Urothelial
Carcinoma of the Bladder.
Clin Genitourin Cancer. 2025;23:102399. PubMed Abstract available
LIU L, He LY, Zhang PY, Xiao Y, et al Neuroendocrine carcinoma of the bladder: do they have a worse prognosis? A large
retrospective cohort study by propensity score matching analysis.
Int J Surg. 2025;111:6435-6440. PubMed Abstract available
LIU L, Li JP, Gao LX, An L, et al Risk factors for acute kidney injury following radical cystectomy: a systematic
review and meta-analysis.
Int J Surg. 2025;111:6330-6342. PubMed Abstract available
MA B, Ma C, Long X, Jiang L, et al Stromal reprogramming in urachal cancer: Fibroblast activation protein and
collagen remodeling drive immune-suppressive niches and immunotherapy resistance.
Int Immunopharmacol. 2025;163:115204. PubMed Abstract available
GRIMMEISEN M, Wang X, Weldle M, Sartory K, et al Synthesis and Evaluation of Trehalose-Based Mertansine Warheads for Bacillus
Calmette-Guerin Delivery of Anticancer Agents.
Chembiochem. 2025;26:e202500390. PubMed Abstract available
OHMOTO A, Kitahama K, Shigematsu Y, Hayashi N, et al Genomic features of bladder neuroendocrine carcinoma with composite histology.
Histol Histopathol. 2025;40:1547-1554. PubMed Abstract available
DE ANGELIS M, Jannello LMI, Siech C, Di Bello F, et al Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or
Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients.
J Racial Ethn Health Disparities. 2025;12:3284-3293. PubMed Abstract available
ZHANG H, Tang K, Chen Y, Chen G, et al Downregulated of CTGF reveals mechanism, remodels immune microenvironment,
modulates drug sensitivity in bladder cancer.
Future Sci OA. 2025;11:2560297. PubMed Abstract available
JUHASZ D, Csizmarik A, Varadi M, Bacso D, et al Lymphovascular Invasion is Predictive for Adjuvant Platinum Therapy Benefit in
Urothelial Bladder Cancer.
Clin Genitourin Cancer. 2025 Sep 1:102421. doi: 10.1016/j.clgc.2025.102421. PubMed Abstract available
MATSUBARA N, Loriot Y, Banek S, Valderrama BP, et al Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with
Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder
Cancer: An Analysis of the Global ANNAR Biomarker Study.
Eur Urol Oncol. 2025 Sep 22:S2588-9311(25)00201. PubMed Abstract available
DU Y, Sui Y, Tao Y, Cao J, et al Comprehensive Assessment of Tumor Stromal Heterogeneity in Bladder Cancer by Deep
Learning and Habitat Radiomics.
Acad Radiol. 2025 Sep 22:S1076-6332(25)00799-8. doi: 10.1016/j.acra.2025. PubMed Abstract available
YONG ZONG AT, Yap WK Global Research Trends in Bladder Cancer Biomarkers: A Bibliometric Analysis.
Cureus. 2025;17:e90724. PubMed Abstract available
LIN N, Zhou Y, Li Y, Lin L, et al Circulating tumor DNA and Urinary tumor DNA: useful biomarkers for bladder cancer
detection.
Expert Rev Mol Diagn. 2025 Sep 22. doi: 10.1080/14737159.2025.2565273. PubMed Abstract available
BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al Role of myeloid-derived suppressor cells in bladder cancer and targeted
therapeutic strategies.
Gene. 2025 Sep 20:149772. doi: 10.1016/j.gene.2025.149772. PubMed
LIEDBERG F, Hagberg O, Beijert IJ, Aljabery F, et al Applicability of the European Association of Urology 2021 Prognostic Model for
Non-muscle-invasive Bladder Cancer in a Swedish Population-based Cohort.
Eur Urol Open Sci. 2025;80:33-37. PubMed Abstract available
SUN Y, Yi X, Zhou C, Huang Y, et al PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and
Metastasis in Bladder Urothelial Carcinoma.
Hum Mutat. 2025;2025:2227219. PubMed Abstract available
BUKAVINA L, Isali I, Parekh S, Psutka S, et al Genetic susceptibility and environmental risk factors in bladder cancer: Evidence
from the UK biobank.
Bladder Cancer. 2025;11:23523735251370863. PubMed Abstract available
RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al Interplay of KIR2DL5, nitric oxide, and tobacco smoking in predisposition to
bladder cancer.
Front Cell Dev Biol. 2025;13:1632101. PubMed Abstract available
DEL GIUDICE F, Santarelli V, Laszkiewicz J, Li S, et al The influence of immunocompromised status on recurrence and progression free
survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing
transurethral resection of bladder tumor (TURBT) and adjuvant intravesical
bacillus Calmette Guerin (BCG
Urol Oncol. 2025 Sep 19:S1078-1439(25)00254. PubMed Abstract available
ETXANO J, Lopez-Maseda A Clinical applications of bladder magnetic resonance imaging: Beyond the VI-RADS(R)
classification.
Radiologia (Engl Ed). 2025;67:101668. PubMed Abstract available
MIAO Z, Xu A, Shen G, Tang S, et al Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate
bladder cancer chemoimmunotherapy.
J Control Release. 2025;387:114246. PubMed Abstract available
YING W, Li D, Feng N, Wei W, et al LncRNA DGUOK-AS1 Promotes Bladder Cancer Progression by Enhancing EFTUD2
Stability.
Cancer Res Treat. 2025 Sep 18. doi: 10.4143/crt.2025. PubMed Abstract available
CHENG Y, Zhou K, Chen Y, Mei Y, et al Concurrent Ferroptosis and Pyroptosis Induced by a Dual-Organelle-Targeted Type
I/II AIE Photosensitizer for Bladder Cancer Immunotherapy.
Angew Chem Int Ed Engl. 2025 Sep 18:e202509783. doi: 10.1002/anie.202509783. PubMed Abstract available
ALONSO JCC, Goncalves JM, de Arruda Camargo GC, de Oliveira G, et al Dual molecular axis of resistance and immunoresponsiveness to BCG in pT1
non-muscle invasive bladder cancer: Insights from HER-2, SERBP1, HABP4, and IFN-gamma
profiling.
Tissue Cell. 2025;98:103137. PubMed Abstract available
ZHANG T, Zhang H, Qi J, Jiang S, et al Hollow Dodecahedral Nanocages for Reliable Multi-Level Differentiation of
Urological Cancers through Non-Invasive Metabolic Fingerprinting.
Anal Chem. 2025;97:20622-20631. PubMed Abstract available
JANG A, Tripathi N, Lanka SM, Kumar HLS, et al Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab:
a path to cure?
Oncologist. 2025;30:oyaf259. PubMed Abstract available
VAN TASSEL E, Howell J, Walls K, Crabtree W, et al Outcome of atypical urothelial cells (AUC) in patients without prior history of
urothelial carcinoma.
J Am Soc Cytopathol. 2025;14:334-340. PubMed Abstract available
TATAR AC, Loghin A, Nechifor-Boila A, Raicea A, et al IHC-based molecular classification in muscle-invasive urothelial bladder
carcinoma: Prognostic and predictive value toward a clinically applicable IHC
marker panel - A systematic review.
Crit Rev Oncol Hematol. 2025;214:104868. PubMed Abstract available
GRIVAS P, Moon HH A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and
Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.
Target Oncol. 2025;20:743-754. PubMed Abstract available
POWLES TB, Van der Heijden MS, Loriot Y, Bedke J, et al Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic
urothelial carcinoma: 2.5-year median follow-up of the phase III
EV-302/KEYNOTE-A39 trial.
Ann Oncol. 2025;36:1212-1219. PubMed Abstract available
GRIVAS P, Aragon-Ching JB, Bellmunt J, Loriot Y, et al Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term
Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms
or Toxicity from the JAVELIN Bladder 100 Trial.
Eur Urol Oncol. 2025;8:941-951. PubMed Abstract available
JAIN RK, Swami U, Bilen MA, Gebrael G, et al Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible
Advanced Urothelial Carcinoma: The PemCab Trial.
Eur Urol Oncol. 2025;8:952-960. PubMed Abstract available
CAO M, Yang G, Zhao T, Zhang L, et al Development and Validation of the UriMee Model: A Methylation-based Diagnostic
Tool for Early Diagnosis of Urothelial Carcinoma.
Eur Urol Oncol. 2025;8:899-908. PubMed Abstract available
GUO E, Chen L, Xu L, Zhang D, et al Optimizing bladder magnetic resonance imaging: accelerating scan time and
improving image quality through deep learning.
Abdom Radiol (NY). 2025;50:4772-4782. PubMed Abstract available
RUTTEN VC, Hesseling SAW, Franckena M, Zuiverloon TCM, et al Carbon footprint and staff demands of surgery and chemoradiation for
muscle-invasive bladder cancer.
BJU Int. 2025 Sep 3. doi: 10.1111/bju.16876. PubMed Abstract available
FAZILI A, Jazayeri SB, Rose KM, Guske C, et al Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate
poor long-term survival following immediate radical cystectomy.
BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895. PubMed Abstract available
CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al Prospective health-related quality of life in women undergoing radical cystectomy
and urinary diversion.
BJU Int. 2025;136:728-737. PubMed Abstract available
KALEN E, Ginstman C, Liedberg F, Hagberg O, et al Incidence and risk factors for postoperative vaginal events following radical
cystectomy for bladder cancer: a nationwide population-based study.
BJU Int. 2025 Sep 20. doi: 10.1111/bju.70004. PubMed Abstract available
STOCKEM CF, Gil-Jimenez A, Ali H, van Dorp J, et al Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus
Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
Clin Cancer Res. 2025;31:3897-3906. PubMed Abstract available
KITAMURA H, Nishiyama N Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and
future directions.
Curr Opin Urol. 2025 Sep 8. doi: 10.1097/MOU.0000000000001331. PubMed Abstract available
OUALLA K, Alem M, Teoh J Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer.
Curr Opin Urol. 2025 Sep 15. doi: 10.1097/MOU.0000000000001334. PubMed Abstract available
WONG CH, Leung DK, Gontero P, Teoh JY, et al Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer:
mechanisms, clinical evidence, and practical implementation.
Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001345. PubMed Abstract available
GABRIEL PE, Horowitz A, Sfakianos JP, Xylinas E, et al Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive
bladder cancer: a narrative review.
Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001343. PubMed Abstract available
DING D, Qian L, Jin D, Zhou X, et al Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of
Residual Bladder Cancer: A First-in-Human Study.
Eur Urol. 2025 Sep 19:S0302-2838(25)00493-2. doi: 10.1016/j.eururo.2025. PubMed
ZUGMAN M, Carneiro A, Maluf FC Challenging the Guidelines: Rethinking Neoadjuvant Therapy for Histologic
Subtypes of Bladder Cancer.
Eur Urol. 2025 Sep 17:S0302-2838(25)00510-X. doi: 10.1016/j.eururo.2025. PubMed
HECK MM, Lehmann J, Amiel T, Rubben H, et al Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph
Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy.
Eur Urol. 2025 Sep 17:S0302-2838(25)00489-0. doi: 10.1016/j.eururo.2025. PubMed Abstract available
PILALA KM, Koroneou S, Papadimitriou MA, Panoutsopoulou K, et al Loss of METTL3 m6A methyltransferase results in short-term progression and poor
treatment outcome of bladder cancer patients.
Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70147. PubMed Abstract available
TILLU N, Dovey Z, Choudhary M, Venkatesh A, et al Open Versus Robotic Radical Cystectomy With Intracorporeal Neobladder: A
Decade-Long Single-Surgeon Experience.
Int J Urol. 2025;32:1234-1242. PubMed Abstract available
URABE F, Tashiro K, Imai Y, Iwatani K, et al Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in
Patients With Advanced Urothelial Carcinoma Treated With First-Line
Platinum-Based Chemotherapy: A Multicenter Collaborative Study.
Int J Urol. 2025;32:1147-1156. PubMed Abstract available
RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and
Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of
Signal Transducer and Activator of Transcription 3.
Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224. PubMed Abstract available
YILDIZ AK, Bayraktar A, Kacan T, Demir DO, et al Two different protocols in single, immediate, postoperative intravesical
chemotherapy after transurethral resection in suspected, low-risk,
non-muscle-invasive bladder cancer.
Int Urol Nephrol. 2025 Aug 28. doi: 10.1007/s11255-025-04767. PubMed Abstract available
NECCHI A, Galsky MD, Dizman N, Aggen DH, et al End Points for the Next-Generation Bladder-Sparing Perioperative Trials for
Patients With Muscle-Invasive Bladder Cancer.
J Clin Oncol. 2025 Sep 11:JCO2501608. doi: 10.1200/JCO-25-01608. PubMed Abstract available
DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al Erratum: TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk
Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
J Clin Oncol. 2025 Sep 9:JCO2502053. doi: 10.1200/JCO-25-02053. PubMed
GUTIERREZ J, Ayub A, Piva SE, Shirk JD, et al IP11-07 A 3D Tumor Map for the Surgical Management of Bladder Cancer: Feasibility
and Preliminary Analysis: Erratum.
J Urol. 2025;214:458. PubMed
WANG Y, Jerome NA, Kelleher AJ, Henderson ML, et al TRIM29 promotes bladder cancer invasion by regulating the intermediate filament
network and focal adhesion.
Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03557. PubMed Abstract available
XIE J, Zhang H, Wang K, Ni J, et al Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer
angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and
enhancing NCF2 transcription.
Oncogene. 2025 Sep 17. doi: 10.1038/s41388-025-03575. PubMed
WESTERMAN ME, Delacroix SE Jr Editorial Comment: Muscle-Invasive Bladder Cancer Treatment Selection in an
Emerging Treatment Era: A Patient Preference Study.
Urology. 2025 Sep 4:S0090-4295(25)00838-6. doi: 10.1016/j.urology.2025. PubMed
LI C, Liu J, Wang L, Xiong W, et al Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer
immunotherapy by inhibiting CD276 expression.
BMC Cancer. 2025;25:1404. PubMed Abstract available
HSIEH KL, Huang KH, Chang CP, Tsai HW, et al CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism
contributing to therapeutic resistance in T24 cells.
PLoS One. 2025;20:e0331289. PubMed Abstract available
KATO T, Okauchi N, Motegi T, Sakurai M, et al Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
PLoS One. 2025;20:e0332825. PubMed Abstract available
